Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Neutral endopeptidase inhibition lacks clinical utility in hypertension; challenges its therapeutic role and redirects research to alternative pathways.
Although atrial natriuretic peptide levels were significantly increased, candoxatril 200 mg twice daily for 28 days did not produce a clinically relevant fall in blood pressure. Our results cast some doubt upon the role of neutral endopeptidase inhibition in the treatment of unselected hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Bevan et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: